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ZD1839 (‘Iressa’) is an orally active, selective epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR–TKI), which
blocks signal transduction pathways implicated in proliferation and survival of cancer cells, and other host-dependent processes
promoting cancer growth. Permanent downstream activation of the mitogen-activated protein kinase pathway can theoretically
bypass the upstream block of epidermal growth factor receptor-dependent mitogen-activated protein kinase activation at the
epidermal growth factor receptor level. We investigated the impact of epidermal growth factor receptor content, p53 status
and mitogen-activated protein kinase signalling status on ZD1839 sensitivity in a panel of human tumour cell lines: seven head
and neck cancer cell lines and two colon cancer cell lines (LoVo, HT29) with derivatives differing only by a speciﬁc
modiﬁcation in p53 status (LoVo p53 wt + p53 mut cells, HT29 p53 mut + p53 wt rescued cells). The antiproliferative activity
of ZD1839 was evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide test. ZD1839 concentrations
ranged from 0.2–200 mM (48 h exposure). Epidermal growth factor receptor expression, p53 status and p42/p44 (for testing
a constitutively active mitogen-activated protein kinase pathway status) were determined by competition analysis (Scatchard
plots), denaturing gradient cell electrophoresis and Western blot, respectively. Epidermal growth factor receptor levels ranged
from 388 to 33794 fmol mg
71 protein, a range that is similar to that found in head and neck tumours. The IC50 values for cell
sensitivity to ZD1839 ranged from 6 to 31 mM and a signiﬁcant inverse correlation (P=0.022, r=0.82) between IC50 values and
epidermal growth factor receptor levels was observed. There was no inﬂuence of p53 status on the sensitivity to ZD1839. In
two head and neck cancer cell lines with comparably elevated epidermal growth factor receptor expression, a two-fold higher
ZD1839 IC50 value was found for the one with a constitutively active mitogen-activated protein kinase. In conclusion, ZD1839
was active against cells with a range of epidermal growth factor receptor levels, although more so in cells with higher
epidermal growth factor receptor expression. Activity was unaffected by p53 status, but was reduced in cells strongly
dependent on epidermal growth factor receptor signalling in the presence of an intrinsically activated mitogen-activated
protein kinase pathway.
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Epidermal growth factor receptor (EGFR), through binding to its
physiological ligands, mainly epidermal growth factor (EGF) and
transforming growth factor a (TGFa), is activated through auto-
phosphorylation at deﬁned cytoplasmic tyrosine residues. This
facilitates association with several SH2 domain-containing proteins
including PLC-g, phosphoinositol-3-kinase, Grb2 and src family
kinases. As a result of these interactions, signal transduction path-
ways are stimulated that can modulate several cellular key
functions including proliferative activity and apoptosis (Chen et
al, 1987; Schlessinger, 1994; Mercer, 2000; Schlessinger et al,
2000). One of the well studied intermediary steps concerns the acti-
vation of the proto-oncogene ras. The ampliﬁcation of the erbB
oncogenes, particularly the human EGFR gene erbB-1 and ras
proto-oncogene mutations, has been shown to play a fundamental
role in the progression of different solid tumours, including head
and neck cancer, by acting through the activation of the ras-MAPK
(mitogen-activated protein kinase) pathway (Salomon et al, 1995;
Maurizi et al, 1996; Grandis et al, 1996, 1998).
Epidermal growth factor receptor appears to be a major prog-
nostic factor in head and neck cancer patients (Santini et al,
1991; Dassonville et al, 1993; Etienne et al, 1999). Thus, inhibition
of EGFR represents a potential therapeutic strategy for controlling
cancer growth, particularly in head and neck cancer where the
expression of this receptor is frequently ampliﬁed. The develop-
ment of compounds such as IMC-C225, an EGFR monoclonal
antibody (Baselga, 2001), or ZD1839 (‘Iressa’), an orally active,
selective EGFR tyrosine kinase inhibitor (Ciardiello and Tortora,
2001), is representative of this new therapeutic strategy for the
treatment of cancer. The activity of trastuzumab (Herceptin) has
been shown to be dependent upon Her 2 neu expression levels
(Pegram et al, 1998, Pegram and Slamon, 2000) and it would
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EGFR targeting drugs is linked to EGFR tumour level.
Mutation or inactivation of ras and p53 oncogenes are the most
common genetic events identiﬁed for almost all human cancers,
including head and neck squamous cell carcinomas. In the context
of drugs acting upstream to inhibit the initiation of MAPK path-
way signal transduction, like IMC-C225 or ZD1839, it is
interesting to note that the MAPK pathway can be constitutively
activated by ras mutations (Hoshino et al, 1999). Changes in p53
status have been linked to disease progression, decreased sensitivity
to chemotherapeutic agents and poor prognosis (Cabelguenne et al,
2000). The key role of p53 in controlling cell proliferation and
apoptosis poses the question of whether p53 status inﬂuences the
efﬁcacy of EGFR signal inhibitors.
In this paper, we report the results of studies aimed to assess
whether EGFR expression and intrinsic MAPK pathway status
inﬂuences the cytostatic efﬁcacy of EGFR signal inhibitors. We
used a panel of seven human head and neck cell lines with a wide
range of EGFR expression representative of that found in human
tumours. In addition, the panel consisted of two pairs of cell lines,
that differed in levels of MAPK activity and EGFR expression. In
addition, a model of two human colon cancer cell lines, with speci-
ﬁcally modiﬁed p53 status, was included to analyse the effect of
p53 status on the efﬁcacy of ZD1839.
MATERIALS AND METHODS
Chemicals
ZD1839 was kindly provided by AstraZeneca and a working solu-
tion (50 mM in dimethysulfoxide (DMSO)) was prepared
immediately before use. Human recombinant
125I-EGF (ref. IM
196, speciﬁc activity 4514610
10 Bq/mol, 92.5610
4 Bq/250 ml)
and unlabelled human recombinant EGF (ref. ARN 5100) were
from Amersham. The agents were purchased: Dulbecco’s modiﬁed
eagle’s medium (DMEM), Roswell Park Memorial Institute (RPMI
1640) and glutamine (Whittaker, Verviers, Belgium); foetal bovine
serum (FBS) (Dutscher, Brumath, France); penicillin and strepto-
mycin (Meyrieux, Lyons, France); transferrin and insulin (Flow,
Irvine, Scotland); bovine serum albumin (BSA); phosphate-
buffered saline (PBS); 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) and DMSO (Sigma, St. Quentin Falla-
vier, France).
Cell lines
A panel of seven head and neck cancer cell lines of human origin was
speciﬁcally designed for this study: CAL27, CAL33, CAL60, CAL165,
CAL166 originated from our Institute; Hep-2 and Detroit562 origi-
nated from the American Type Cell Collection (Rockville, MD,
USA). Across all the cell lines, there was approximately a 100-fold
difference in EGFR expression: Hep-2 expressed the lowest EGFR
levels and CAL33 the highest (Table 1). Two pairs of cell lines were
represented in the panel: (1) CAL60 and CAL166, and (2) CAL165
and Detroit562. CAL60 and CAL166 both have high levels of EGFR
expression whereas CAL165 and Detroit562 have relatively low
levels. In addition, MAPK pathway status differed between cell lines
in each pair: CAL166 and Detroit562 have a constitutionally active
MAPK pathway whereas CAL60 and CAL165 do not.
Two groups of cell lines with speciﬁcally modiﬁed p53 status
were also studied. These were obtained from Dr MF Poupon
(CNRS, Institut Curie, Paris) and comprised: (1) LoVo cells (p53
wild-type) plus three derived cell lines (LoVo X2, LoVo X17, LoVo
X19) in which mutated p53 was speciﬁcally introduced; (2) HT29
cells (p53 mutated) plus two derived cell lines (HT29 A3 and HT29
A4) in which p53 wild-type was re-introduced, as described by
Soulie ￿ et al (1999). According to the ﬁndings of other authors
(Pocard et al, 1996), LoVo was arrested in the G1 phase of the cell
cycle after 10 Gy irradiation, while no arrest was obtained after
irradiation of LoVo X2, LoVo X17, LoVo X19 with a mutated
p53 status; HT29 A3 and HT29 A4 were arrested in the G1 phase
after inhibition of pyrimidine synthesis, while no arrest was
obtained with HT29 parental cells, showing the dominant function
of wild-type p53 in the HT29 A3 and HT29 A4 cell lines.
Cells were routinely cultured in DMEM supplemented with 10%
FBS, 2 mM glutamine, 600 mgl
71 insulin, 500 mgl
71 transferrin,
50 000 units l
71 penicillin and 80 mM streptomycin in a fully
humidiﬁed incubator (Sanyo, Japan) at 378C in an atmosphere
containing 8% CO2.
EGFR assay
Epidermal growth factor receptor expression was assayed as
previously described (Olivier et al, 1990). Cells were grown to
80–90% conﬂuence, in 24-well plates, in 10% FBS–DMEM at
378C. Cells were rinsed three times with 500 ml RPMI 1640
containing 0.1% BSA at 2–48C and incubated for 30 min with
the same medium (500 ml per well) at 48C. Total EGF binding
was measured after incubation with 0.2 nM
125I-EGF (3 h, 48C,
0.1% BSA–RPMI); non-speciﬁc binding was measured in the
presence of an excess of unlabelled EGF (20 nM). The content of
the EGFR was determined by incubation in RPMI medium for
3 h at 48C in the presence of increasing concentrations of
125I-
EGF (0.01, 0.02, 0.04, 0.08, 0.12, 0.18, 0.2 nM); for cells expressing
high EGFR concentrations, cells were incubated with 0.2 nM of
125I-EGF with increasing concentrations of unlabelled EGF (0.05,
0.1, 0.2, 0.4, 0.8, 1.6, 3.2, 6.4, 20, 200 nM). Plates were put on
ice to stop the reaction, the supernatant was removed, and cells
were washed twice with PBS containing 0.1% BSA (48C, 500 ml
per well). Cells were solubilized in 1 M NaOH at 378C (500 ml
per well for 30 min). Radioactivity was determined by gamma
counting. The number of receptor sites per cell (N) and the disso-
ciation constant (Kd) were determined by Scatchard analysis (each
point on the Scatchard plots was done in quadruplicate). Cell
number was determined in four wells run in parallel, by resuspend-
ing cells in 200 ml PBS at room temperature and counting with a
hemocytometer. Experiments were performed only in duplicate
because of the intrinsic reproducibility of the assay (CV=7.3%,
n=4).
Determination of MAPK status
The determination of MAPK pathway status was based on the
measurement of phosphorylated p42–p44(activated form of MAPK)
by immunoblot analysis performed in the presence (stimulated EGFR
pathway, medium plus FBS) or absence of serum (non-stimulated
EGFR pathway). No EGF was added. Prior to stimulation by growth
factors, cells were grown in the presence of growth factors (i.e. FBS)
for 48 h followed by a 48-h period in which they were deprived of
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Table 1 Head and neck cell line characteristics
Mean (SD) Intrinsically Mean (SD) IC50
EGFR content active MAPK values (mM)–
Cell line fmol mg
71 protein
a p53 pathway
b 48-h exposure
b
CAL27 8258 (311) mutant no 17.5 (2.4)
CAL33 33794 (624) mutant no 6.1 (0.8)
CAL60 2703 (101) mutant no 11.4 (0.9)
CAL165 721 (52) mutant no 22.9 (13.2)
CAL166 3253 (126) wild-type yes 22.8 (4.8)
Hep-2 388 (27) wild-type no 31.2 (2.4)
Detroit562 668 (45) mutant yes 20.6 (1.5)
aAt least two separate experiments;
bat least three separate experiments. no: acti-
vated pathway only in the presence of growth stimulus (FBS); yes: activated
pathway even in the absence of growth stimulus.
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did not undergo growth factor deprivation and were grown in
medium supplemented with FBS for 72 h. Stimulated (control) or
non-stimulated cells (4610
6) were harvested in 50 ml of lysis buffer,
Laemmli 1X (Laemmli 4X: 1.6 ml Tris-HCL 1 M pH 6.8; 400 mg
sodium dodecyl sulphate (SDS); 2 ml glycerol; 145 ml b-mercap-
toethanol; 12% bromophenol), and were heated for 15 min at
958C. Protein content of the cytosol preparations was determined
by the Bradford method using the Bio-Rad reagent with BSA as stan-
dard. Equal amounts of protein (50 mg/lane) were separated by
12.5% SDS–10% PAGE (polyacrylamide gel electrophoresis) and
transferred onto a nitrocellulose membrane. Pre-stained molecular
weight markers were included in each gel. Membranes were blocked
for 30 min in tris-buffered saline (TBS)-Tween (10 mM Tris-HCl,
pH 7.5; 150 mM NaCl with 0.5% Tween-20) and 5% BSA. After
blocking, membranes were incubated for 12 h with a mouse anti-
human monoclonal anti-MAP kinase activated antibody (Diphos-
phorylated ERK-1&2, anti-DPERK, clone MAPK-YT, dilution of
1/5000, Sigma) in TBS-Tween and 1% BSA. After washing the
membranes three times with TBS-Tween (5 min each), they were
incubated with peroxidase-conjugated secondary antibodies
purchased from Dako (dilution of 1/1000, Glostrup, Denmark).
The chemoluminescence reaction was performed and the membranes
exposed to ECL hyperﬁlm according to the manufacturer’s instruc-
tions (Amersham Pharmacia Biotech, Little Chalfont, UK).
Triplicate determinations were made in separate experiments.
Determination of p53 status
This speciﬁc investigation was performed by Dr P Laurent-Puig
(INSERM U 490, Paris). DNA was ﬁrst extracted and exons 4 to
8 were screened for mutations by denaturing gradient gel electro-
phoresis (DGGE) in accordance with the method described by
Hamelin et al (1993) for exons 5, 7 and 8 and the method of
Gulberg et al (1997) and colleagues for exons 4 and 6. Exon 9
was screened for mutations by the method described by Cabel-
guenne et al (2000). PCR ampliﬁcation products were loaded onto
a 6.5% polyacrylamide gel that contained an appropriate gradient
of urea and formamide. After electrophoresis, gels were stained
with ethidium bromide. Tumours that showed an electrophoresis
variant pattern were ampliﬁed and sequenced for each variant
exon. PCR products were puriﬁed with QIAquick PCR Puriﬁcation
Kit (QIAGEN S.A., Courtabeuf, France) and sequenced on both
strands on an ABI 310 genetic analyser (PE Applied Biosystems,
Courtabeuf, France). A Big Dye Terminator sequencing kit (PE
Applied Biosystems) was used according to the manufacturer’s
instructions, followed by ethanol precipitation, to remove nonin-
corporated dyes. Sequences were analysed by Sequence Analysis
3.0 (PE Applied Biosystems).
Evaluation of ZD1839 antiproliferative activity
Cells were seeded in 96-well microtitre plates (100 ml per well) and
incubated for 48-h to establish exponential growth (initial cell
density was 2000 cells/well for CAL165; 2500 cells/well for CAL27
and Hep-2; 3000 cells/well for CAL33, Detroit562, LoVo and
HT29; 4500 cells/well for CAL166; 5000 cells/well for CAL60). Cells
were then incubated with ZD1839 (0.2–200 mM) for 48 h; eleven
concentrations were tested for each cell line.
Growth inhibition was assessed by the MTT test (described
below (Carmichael et al, 1987)) 48 h after ZD1839 was removed.
Cells were washed with PBS and incubated with MTT for 2 h,
followed by the addition of 100 ml of DMSO. Absorbance at
450 nm was measured using a microplate reader (Labsystems,
Helsinki, Finland) and results were expressed as the relative percen-
tage of absorbance compared with controls. Experimental
conditions were tested in sextuplicate (six wells of the 96-well plate
per experimental condition), and experiments were performed in
triplicate. The dose-effect curves were analysed on Prism software
(GraphPad Software, San Diego, USA). The antiproliferative activ-
ity of ZD1839 was expressed by the IC50 value (concentration
leading to 50% reduction in cell growth measured by MTT).
Statistical analysis
The relationship between EGFR expression and response to ZD1839
was analysed by plotting the IC50 of ZD1839 sensitivity for cell lines
vs EGFR content. The correlation coefﬁcients (r) and the P values
(P50.05 was considered statistically signiﬁcant) were computed
using the program SPSS software (Chigago, IL, USA).
RESULTS
Cell line characteristics
Cell line characteristics are displayed in Table 1. The assessment of
EGFR content conﬁrmed that EGFR expression varied substantially
between cell lines in the panel of head and neck human squamous
cell carcinoma cells. In addition, ﬁve of the seven human head and
neck cell lines were conﬁrmed as having a mutated p53 gene:
CAL166 and Hep-2 were p53 wild-type. Two cell lines, CAL166
and Detroit562, had a constitutively activated MAPK pathway.
The EGFR content in LoVo and HT29 cell lines (parental and
transfected) was 65 to 78 fmol mg
71 protein and 3293 to
3450 fmol mg
71 protein, respectively (Table 2).
Antiproliferative effect of ZD1839 on head and
neck cell lines
Figure 1 shows typical dose–response curves for ZD1839 on
CAL33 and Hep-2 cell lines. IC50 values and other characteristics
for the head and neck cell lines tested are presented in Table 1.
CAL33 cells were found to be the most sensitive to the growth
inhibitory effects of ZD1839 (IC50 6.1 mM), and Hep-2 cells were
the least sensitive (IC50 31.2 mM).
Relationship between EGFR expression and
response to ZD1839
A signiﬁcant inverse correlation was found between ZD1839 IC50
value and EGFR content (P=0.022, r=0.68) (Figure 2). The inclu-
sion of LoVo and HT29 cell lines in the regression analysis
improved the correlation with an r shifting from 0.68 to 0.72
and the P value from 0.022 to 0.004 (not shown).
Inﬂuence of p53 status on cell sensitivity to ZD1839
Cell sensitivity to the growth inhibitory effects of ZD1839 remained
unchanged irrespective of p53 status (Table 2). This was also the
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Table 2 Colon cancer cell lines with speciﬁcally controlled p53 status
Mean (SD) EGFR
content, Mean (SD)
Cell line p53 status fmol mg
71 protein IC50, mM
LoVo wild-type 65 (3) 24.5 (0.5)
LoVo X2 mutant 72 (5) 32.5 (3.2)
LoVo X17 mutant 78 (7) 25.9 (0.3)
LoVo X19 mutant 74 (1) 24.1 (0.7)
HT29 Blk mutant 3293 (47) 9.3 (0.3)
HT29 A3 wild-type 3410 (123) 12.0 (0.2)
HT29 A4 wild-type 3450 (320) 7.9 (0.5)
At least three experiments.
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(HT29 series) and when a p53 mutant was transfected in a p53
wild-type cell line (LoVo series). Overall, HT29 cells were more
sensitive than LoVo cells to the effects of ZD1839; this could be
attributable to the difference in EGFR content between HT29 cells
and LoVo cells (Table 2).
Inﬂuence of MAPK pathway status on cell sensitivity to
ZD1839
Two pairs of cell lines having comparable EGFR levels but with
different MAPK pathway status have been compared (CAL60/
CAL166 and CAL165/Detroit562). Within each pair, the difference
of sensitivity to ZD1839 due to the status of MAPK pathway
depended upon whether the cells had a high or low EGFR content:
for the pair with a high EGFR content, CAL60 (MAPK pathway
not intrinsically active) was found to be twice as sensitive to
ZD1839 as CAL166 (MAPK pathway intrinsically active) with
respective IC50 values of 11.4 and 22.8 mM, whereas for the pair
with low EGFR content, there was no difference in sensitivity
between CAL165 and Detroit562 (Table 1).
DISCUSSION
Overexpression of EGFR predicts a poor prognosis in many
cancers, particularly in head and neck squamous cell carcinomas
(Santini et al, 1991; Dassonville et al, 1993; Salomon et al, 1995;
Maurizi et al, 1996; Grandis et al, 1996, 1998; Etienne et al,
1999), and consequently EGFR is a prime target for anticancer
therapy. For monoclonal antibodies targeting EGFR, it has recently
been shown that high expression of EGFR is associated with a
better efﬁcacy of the biologic agent (Hambek et al, 2001). Other
investigators (Bos et al, 1997) have also provided evidence for a
link between EGFR level and the sensitivity to a EGFR tyrosine
kinase inhibitor; but the debate is still open (Moasser et al,
2001) and data based on a sufﬁcient number of cell lines with a
quantitative determination of EGFR cellular level are still justiﬁed.
We thus examined the relationship between EGFR content of cells
across a representative panel of head and neck cell lines and cell
sensitivity to ZD1839. The present data establish a strong correla-
tion between cell sensitivity of ZD1839 and EGFR expression, with
the highest ZD1839 efﬁcacy in cells with the highest EGFR content,
although the clinical signiﬁcance of this is unknown. The IC50
values reported here are substantially higher than those published
by other investigators (Ciardiello et al, 2000). The used drug
concentrations were dictated by the experimental conditions and,
as compared to in vivo conditions, to a relatively short exposure
of the tumoural cells to the drug (given once). It is normal that,
in vivo, when tumour cells are continuously exposed to the parent
drug, the observed concentrations may be lower; in vivo there is
also the possible presence of active metabolites carrying a part of
the activity, such metabolites are obviously not present in the in
vitro condition. On the other hand, for cell survival in vitro, the
presence of a percentage of serum in the culture medium is needed
and this situation brings growth factors which stimulate the drug
pathway which is targeted by the drug. Other investigators using
similar experimental conditions than ours have recently reported
on ZD1839 IC50 values very close to those reported in this manu-
script (Al-Hazzaa et al, 2001). To match in vivo conditions as
closely as possible, we have deliberately not used serum-free condi-
tions. In additionnal experiments (data not shown), cell lines have
been exposed to a medium supplemented with TGFa (1.10
73–
10 ng ml
71) and EGF (1.10
73–10ngml
71); no differences in
the IC50 values of ZD1839 were observed in any tested cell line.
This suggests that EGFR ligands in the serum-containing medium
were sufﬁcient to saturate EGFR. The present data show a positive
correlation between cell sensitivity of ZD1839 and EGFR expres-
sion. Despite this correlation, antiproliferative activity of ZD1839
continued to be seen at low levels of EGFR expression. The
response to EGFR-targeted agents may be considered as the net
outcome of a multifactorial set of circumstances; EGFR number
per se may only be one component of this, as exempliﬁed by the
data presented here on the inﬂuence of constitutively activated
MAPK on response.
Previous data have shown that ZD1839 has numerous effects on
tumour cells including cell cycle arrest, increase in apoptosis and
reduction in cell proliferation (Ciardiello et al, 2000; Sirotnak et
al, 2000). It is clear that p53 status and EGFR signalling must
interfere at the level of cell cycle control and apoptosis. Thus, data
examining the role of p53 in the efﬁcacy of EGFR targeting (with
an adequate cellular model controlling p53 status only) need to be
provided. Two recent papers suggest an interaction between EGFR
and p53 (Donato et al, 2000; Akerman et al, 2001). As a conse-
quence of this, analysis of the possible inﬂuence of p53 mutation
and intrinsic MAPK pathway status was an additional objective
of the present study. In head and neck squamous cell carcinomas
the pivotal role of the tumour suppressor gene p53 in determining
the balance between cell proliferation and cell death is well estab-
lished (Mineta et al, 1998; Temam et al, 2000). In the present panel
of seven head and neck cell lines, the high proportion of cell lines
mutated for p53 concurs with the mutational status of p53 in oral
carcinomas and supports the clinical relevance of the experimental
model used in this study. However, this head and neck cell line
panel did not permit a clear conclusion on whether p53 status
impacts on ZD1839 sensitivity, due to the fact that other
confounding cellular factors, such as EGFR content, also inﬂuence
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cancer cell lines (LoVo and HT29) was added. These cell lines
constitute an appropriate model for speciﬁcally testing the impact
of p53 status because they differ only with respect to their genetic
alterations concerning p53. Clearly, on this experimental basis, the
cellular p53 status did not inﬂuence ZD1839 efﬁcacy. On the other
hand, it has been recently shown that in vitro manipulations of p53
status could inﬂuence EGFR expression level (Ludes-Meyers et al,
1996). In the present study there was no inﬂuence of p53 status
on EGFR content. This observation was not only true for a situa-
tion where wild-type p53 was transfected in a p53 mutant cell line,
but also for the opposite situation, where p53 mutant was trans-
fected in a wild-type p53 cell line.
In contrast with the experiments testing the effect of p53 status,
the situation for MAPK pathway status depended upon the model
used. It is well known that ras mutations lead to a constitutionally
active MAPK pathway, but the inverse is not necessarily true, and
spontaneous phosphorylation of p42/p44 can also be encountered
in tumours with intact ras (Hoshino et al, 1999; Bar-Sagi and Hall,
2000). Thus, in the present panel, cells with an intrinsically active
MAPK pathway were not to be a priori considered as ras mutated.
Two pairs of cell lines having, for each pair, similar EGFR content
and different intrinsic MAPK pathway status were at our disposal
in the panel: one pair with relatively high EGFR levels (CAL60/
CAL166) exhibiting a difference in sensitivity to ZD1839 between
each cell line of the pair, and the other pair of cell lines with rela-
tively low EGFR levels (CAL165/Detroit562) showing no difference
in sensitivity to ZD1839 between each cell line of the pair. A key
ﬁnding from these results was that even in the presence of a consti-
tutively active EGFR–MAPK pathway, which could theoretically
bypass an upstream signal blockade, the application of the
EGFR–TKI ZD1839 could still lead to the abrogation of cell prolif-
eration. In addition, it was shown that MAPK pathway status may
inﬂuence ZD1839 activity only in tumour cells that are strongly
dependent upon EGFR signalling (high EGFR content). We are
conscious that these results are preliminary in nature but they
suggest that an intrinsically activated MAPK pathway could repre-
sent a source of intrinsic resistance to ZD1839.
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